Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifidobacterium Triple Live Capsule for Adjuvant Treatment of Mental Disorders
ChiCTR1900024126Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jul 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in major depressive disorder (MDD) and bipolar disorder (BD) comparing Bifidobacterium triple live capsule with Placebo capsule (2 arms). Primary endpoints: Bone density, HAMD and 3 more. Started Jul 2019; status: recruiting.
02
Drugs
Golden Bifid
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on ChiCTR1900024126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024126.